Michael Secora

Michael Secora

Former Chief Financial OfficeratRecursion Pharmaceuticals· In proxies 2021–2024

Pay in FY2024+12% from the year before · Recursion Pharmaceuticals stock -31.4% the same year

Michael Secora was paid $5.0M in FY2024 (Dec), up 12%. Recursion Pharmaceuticals stock fell 31.4% that year.

Pay$100 in the stock at the end of FY21 → $39
Pay is from the Summary Compensation Table of each Recursion Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Recursion PharmaceuticalsPublic company · 5 yr
    • Former Chief Financial Officer2021 – Present · 5 yrStock in role -86%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?